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Background: Although local treatments for cervical intraepithelial neoplasia (CIN) are highly effective, it has been
reported that treated women remain at increased risk of cervical and other cancers. Our aim is to explore the risk
of developing or dying from cervical cancer and other human papillomavirus (HPV)- and non-HPV-related
malignancies after CIN treatment and infer its magnitude compared with the general population.
Materials and methods: Design: Systematic review and meta-analysis. Eligibility criteria: Studies with registry-based
follow-up reporting cancer incidence or mortality after CIN treatment. Data synthesis: Summary effects were
estimated using random-effects models.
Outcomes: Incidence rate of cervical cancer among women treated for CIN (per 100 000 woman-years). Relative risk
(RR) of cervical cancer, other HPV-related anogenital tract cancer (vagina, vulva, anus), any cancer, and mortality, for
women treated for CIN versus the general population.
Results: Twenty-seven studies were eligible. The incidence rate for cervical cancer after CIN treatment was 39 per
100 000 woman-years (95% conﬁdence interval 22e69). The RR of cervical cancer was elevated compared with the
general population (3.30, 2.57e4.24; P < 0.001). The RR was higher for women more than 50 years old and
remained elevated for at least 20 years after treatment. The RR of vaginal (10.84, 5.58e21.10; P < 0.001), vulvar
(3.34, 2.39e4.67; P < 0.001), and anal cancer (5.11, 2.73e9.55; P < 0.001) was also higher. Mortality from
cervical/vaginal cancer was elevated, but our estimate was more uncertain (RR 5.04, 0.69e36.94; P ¼ 0.073).
Conclusions: Women treated for CIN have a considerably higher risk to be later diagnosed with cervical and other HPV-
related cancers compared with the general population. The higher risk of cervical cancer lasts for at least 20 years after
treatment and is higher for women more than 50 years of age. Prolonged follow-up beyond the last screening round
may be warranted for previously treated women.
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The introduction of systematic call and recall screening
programmes has resulted in a profound decrease in the
incidence and mortality from cervical cancer.1 This is
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Volume 31 - Issue 2 - 2020neoplasia (CIN)] can be detected and treated.2 Although
local cervical treatment of CIN is highly efﬁcacious, treated
women continue to represent a high-risk group, as the
recurrence rate for high-grade preinvasive disease can be as
high as 5%e10%.3 Furthermore, and despite increased
surveillance, these women have been reported to have a
higher risk of invasive cervical cancer than the general
population for several years after treatment.4e8 The impact
of different treatment methods (excisional or ablative) on
the risk of future invasion remains largely unclear.
This increase in risk may be caused by persistent or
recurrent human papillomavirus (HPV) infections or residual
preinvasive disease that can be more difﬁcult to detect and
prevent.9,10 It has also been suggested that women whohttps://doi.org/10.1016/j.annonc.2019.11.004 213
Annals of Oncology I. Kalliala et al.develop CIN constitute a subgroup of infected women who
are particularly sensitive to the infection and as a result
rapidly acquire reinfections after local treatment. This pla-
ces them at possibly higher risk of not only cervical, but also
other HPV-related neoplasms.
Estimating the relative risk (RR) of cervical cancer in
treated women compared with those who were not treated
is important for determining the age of the last screening
and in formulating follow-up strategies that would allow risk
stratiﬁcation for this high-risk population. In most Western
societies, screening for treated women is similar to that of
the general population and this is not more intensive or
different in length. The age of the last screening, at the age
of 60 or 65 years in most countries, has been previously
debated,11 particularly in the context of a previous local
treatment.8,12,13 In the USA, previously treated women are
advised to attend screening for 20 years after treatment,
even if this extends beyond the age of 65 years,13 although
this is not practised in most European settings. High-quality
reviews that summarise effect estimates may inform policy
makers and allow more tailored screening strategies for this
population. Furthermore, awareness of the risk for other
HPV-related malignancies may also increase awareness and
early detection for these neoplasms.
A systematic review and meta-analysis published 13 years
ago reported a 56 per 100 000 woman-years incidence rate
(IR) of cervical cancer after CIN treatment, which was
thought to be three times greater than the expected rate in
the UK.14 This meta-analysis included predominantly small
studies without centralised follow-up, did not compare to
an untreated reference population, and did not explore the
risk of non-cervical neoplasms. Since then, there have been
several new large population-based studies with nationwide
or regionwide follow-up on all cancer-related incidences
and mortality. Pooled effect estimates from these studies
have not been summarised and reported.
The aim of this review was to the estimate the absolute
risk of developing or dying from cervical cancer, and HPV-
and non-HPV-related malignancies after CIN treatment, and
to further explore how this compares with the risk reported
in the general population.
MATERIALS AND METHODS
Weregistered our protocolwith PROSPERO (CRD42018111659)
and followed the PRISMA guidelines for reporting
(supplementary Table S1, available at Annals of Oncology
online).15Eligibility criteria and outcomes
We included studies reporting on the absolute incidence of
cervical cancer or relative incidence and mortality of cervi-
cal, HPV-related, or non-HPV-related cancers after local
treatment of CIN. Studies were eligible if they used
nationwide or regionwide cancer registries as a source of
follow-up data, and presented data with at least 5 years of
follow-up.We excluded studies where hysterectomy was the
primary treatment of CIN in the analysis for cervical cancer214 https://doi.org/10.1016/j.annonc.2019.11.004incidence. When a subset of the study population had
hysterectomy, these women were removed if data were
provided separately. If this was not possible, the study was
retained if the proportion of women undergoing hysterec-
tomy was less than 10%. For other cancers, we also included
studies where the primary CIN treatment was hysterectomy.
Studies assessing recurrence rates in women with micro-
invasive and invasive cervical cancer were excluded. Studies
reporting on the outcomes of interest after treatment of
both CIN and invasive disease without providing separate
data were excluded. In cases of duplicate studies reporting
on the same population, we retained the largest study for
analysis. We preferred cohort studies to case-control, and
those using a ‘lag’ period of at least 6 months between
treatment and beginning of cancer incidence follow-up, to
avoid the inclusion of cancer cases present but missed at
the time of the original treatment. Data from duplicate
studies were included in subgroup analyses, where appli-
cable. There were no language or other restrictions.
For each outcome of interest (incidence and mortality of
cervical, other HPV-related, non-HPV-related malignancies)
we explored both absolute and relative measures compared
with the reference population. We focused on the IR
deﬁned as the number of cases or deaths per woman-years.
We also included RR or hazard ratio (HR) when the refer-
ence group included women without CIN, and standardised
incidence ratio (SIR) or standardised mortality ratio (SMR)
when the general population was used as a reference.
Literature search, data extraction and assessment of risk of
bias
We searchedMedline, Embase, and Central from inception to
18 August 2018 for eligible studies (search strategy in
supplementary Methods, available at Annals of Oncology
online). From each study, we extracted, independently and in
duplicate, data on the study design, setting, demographics,
CIN grades, treatment method used, length of the follow-up,
data sources, and outcomes. We also extracted data on the
reference population where available. We extracted data on
the absolute and relative incidence andmortality for different
follow-up time periods, age groups, histological CIN grades,
and for each treatment techniquewhen thesewere provided.
Disagreements were resolved by discussion.
Our objective was to explore the absolute and relative
incidence of malignancies in women previously treated for
CIN versus untreated populations. We therefore used the
Quality in Prognosis Studies (QUIPS) tool16 (supplementary
Methods, available at Annals of Oncology online) to explore
the risk of bias at the study level independently and in
duplicate using six domains: study participation, study
attrition, prognostic factor measurement (i.e. treatment of
CIN), outcome measurement, adjustment of outcome
measurements, and statistical analysis and reporting.
Data synthesis and assessment of heterogeneity
We ﬁtted a generalised linear mixed model using the log
transformation to synthesise the raw IRs of cancer amongstVolume 31 - Issue 2 - 2020
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Figure 1. PRISMA ﬂow chart.
I. Kalliala et al. Annals of Oncologytreated women per 100 000 woman-years.17,18 We back-
transformed the summary absolute IRs to the original
scale to ease interpretation. The between-study variance
was estimated using the maximum likelihood method.19
Studies reporting on relative cancer incidence and mor-
tality used RR, HR, SIR, or SMR to compare the risks be-
tween treated and untreated or the general population.
Since the prevalence of CIN treatment or cervical cancer in
the general population is low, we considered SIR, HR, and
RR to be comparable and therefore meta-analysed them
jointly.20,21 The pooled RRs, along with their 95% conﬁ-
dence interval (CI) for cancer incidence and mortality, were
estimated using the random-effects model, since we
anticipated clinical and methodological heterogeneity. We
estimated the summary cancer incidence or mortality RR
and its 95% CI using the Hartung-Knapp-Sidik-Jonkman
method22,23 to handle meta-analyses with a small number
of studies. The between-study variance was estimated using
the Paule-Mandel estimator24,25 for the relative estimates,
and its 95% CI using the Q-proﬁle approach.26 Full details of
the analysis are included in supplementary Methods,
available at Annals of Oncology online.
For all meta-analyses, we quantiﬁed the between-study
heterogeneity using the I2 statistic. In meta-analyses of
relative effects, we also calculated a 95% CI for the I2 statis-
tic.27e29 If there was evidence of substantial heterogeneity
and more than two studies were available, the possible
reasons for this were investigated through sensitivity and
subgroup analyses (supplementary Methods, available at
Annals of Oncology online). We calculated 95% prediction
intervals (PIs) for the absolute and relative treatment effect
estimates accounting for between-study heterogeneity to
obtain a range in which the predicted true treatment effect in
a new study is expected to lie.30Wewere not able to formally
assess for publication bias and small-study effects in our
meta-analyses of relative effects due to the small number of
studies (<10) in each outcome.31 The effect of publication
bias in studies assessing prevalence or absolute incidence of
cancer is not well established, sowe did not perform any such
analysis. All analyses were carried out in R V.3.4.332 using the
metafor package33; all forest plots were plotted using the
meta package.34RESULTS
Characteristics of studies
We retrieved 13 171 potentially eligible papers, of which 27
publications from 24 cohort studies met the inclusion
criteria (Figure 1).4,5,7,8,35e57 The characteristics of the
studies are reported in Tables 1 and 2. All studies except
two described retrospective cohorts; one was a nested
case-control study,38 and one reported the pooled analysis
for three cohorts within The Netherlands.45 The mean or
median follow-up time varied from 5 to 27.5 years. The
largest study included 150 883 women and the smallest 72.
More details are found in supplementary Results, available
at Annals of Oncology online.Volume 31 - Issue 2 - 2020Seven additional studies met the inclusion criteria,46,58e63
but were excluded from the main analysis because they
presented duplicate results of the same population. Some
data from the duplicate studies were used in the subgroup
analyses.46 The reasons for preferential inclusion of a study
over the duplicate on the same population are explained in
supplementary Table S2, available at Annals of Oncology
online.
Thirteen cohorts reported on absolute7,8,35,41e43,45e49,51e53
and 10 cohorts on relative7,8,35,41,42,46,48,49,51e53 cervical can-
cer incidence after CIN treatment. The treatment methods
used were reported in eight cohorts.7,35,42,43,45e49 Four
cohorts7,35,48,49,53 excluded women treated primarily with
hysterectomy (supplementary Results, available at Annals
of Oncology online). Seventeen cohorts provided data on
the relative incidence of other cancers than cervical can-
cer5,8,36e40,44,46,47,50e52,54e57 Ten cohorts reported on
relative HPV-related non-cervical female anogenital cancer
incidence [six on vaginal, seven on anal, seven on vulvar,
and four on cervical plus vaginal (not separately) cancer
relative incidence].5,8,36,37,40,44,46,47,50,52,56 Nine cohorts
reported on relative non-HPV-related cancer incidence
(ﬁve on endometrial, ﬁve on ovarian, ﬁve on breast, ﬁve
on lung, and ﬁve on colorectal cancer relative inci-
dence).39,46,50e52,54e57 One cohort4 reported on relative
cervical cancer mortality, and two5,47 on relative cervico-
vaginal cancer mortality after treatment of CIN.https://doi.org/10.1016/j.annonc.2019.11.004 215
Table 1. Characteristics of studies on cervical cancer incidence after treatment of cervical intraepithelial neoplasia (CIN)
Author, year Country Study design N treated
(women-years)
Treatment method Degree of
treated CINa
Follow-up
time (median)b
Lag periodc N cervical
cancers
among
treated
Ascertainment of
(a) exposure (i.e. CIN)
(b) outcome
(i.e. cervical cancer)
Reference
population
Effect
estimate
Evans, 2003 UK Retrospective
cohort
59 519 (477 069) NR (<10% had
hysterectomy; NR if all
women had Tx but
most probably did
because only CIN3
cases were included)
CIN3 8 yearsb No 194 (a) TCR
(b) Prospective f-u
(until 1982) for patients
with CIN diagnosed
before 1971;
retrospective f-u
through NHS Cancer
Registry for patients
with CIN diagnosed
after 1970
General female
population covered
by TCR
SIR
Kalliala,
2005, 2007
Finland Retrospective
cohort
7466 (100 284) CKC, LLETZ, LC, LA, CT CIN1e3 11.9 yearsb 0.5 years 22 (a) Records of Helsinki
University Hospital
(b) Finnish Cancer
Registry
General female
population from
Southern Finland
SIR
Taylor, 2006 USA Retrospective
cohort
56 020 (3 047 808) NR (because Tx period
was 1988e1999, we
assumed that
hysterectomy was
probably carried out in
relatively few cases)
CIN3 5 years No 168 (a) and (b) California
Cancer Registry
General female
population from
California
SIR
Strander,
2007
Sweden Retrospective
cohort
NR (742 765)
(only women
treated during
1981e2000)
NR (the Swedish
Cancer Register does
not include data on
treatment; we
excluded women
treated during 1958
e1980 when
hysterectomy was
common for CIN3, and
we only included
women treated during
1981e2000)
CIN3 NR (17.5 yearsb
for the whole
study period)
1 year 327 (a) and (b) Swedish
Cancer Registry
General Swedish
female population
SIR
Melnikow,
2009
Canada Retrospective
cohort
37 142 (391 892) CKC, LLETZ, LC, LA, CT CIN1e3 10.6 yearsb 0.5 years 145 (a) British Columbia
Cancer Agency cytology
database
(b) British Columbia
cytology database and
British Columbia
Cancer Registry
Women (21 years
old) from British
Columbia cytology
database with 3
consecutive normal
smears and no
previous Tx for CIN
RR (unadjusted)
McCredie,
2010
New Zealand Retrospective
cohort
72 (1699) CKC CIN3 27.5 years No cancer
during the
ﬁrst w2.5 yearsc
7 (a) Records of National
Women’s Hospital
(b) Medical records,
histopathological
review or cancer and
death registries
General female
population from
New Zealand
SIR
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Table 1. Continued
Author, year Country Study design N treated
(women-years)
Treatment method Degree of
treated CINa
Follow-up
time (median)b
Lag periodc N cervical
cancers
among
treated
Ascertainment of
(a) exposure (i.e. CIN)
(b) outcome
(i.e. cervical cancer)
Reference
population
Effect
estimate
Mitchell,
2002
Australia Retrospective
cohort
6849 (42 463) NR (hysterectomies
were excluded; NR if all
women had Tx)
CIN2e3 6.2 yearsb 1 year 15 (a) and (b) VCGS Women from VCGS
with (i) no history
of CIN2þ, (ii)
negative Pap test
during the years
when CIN2þ was
diagnosed in cases,
and (iii) available
Pap test or
histology before
study ends
RR (unadjusted)
Jakobsson,
2011
Finland Retrospective
cohort
26 876
(226 510)
Excision (CKC, LLETZ,
LC); Ablation (LA,
electrocoagulation, CT);
other (other excision,
cervix amputation etc.)
CIN1e3a 8.4 yearsb f-u started at
end of calendar
year of CIN
treatmentd
23 (a) National Hospital
Discharge Register
(b) Finnish Cancer
Registry
General Finnish
female population
SIR
Kocken,
2011
The Netherlands Pooled analysis
of 2 RCTs and
1 prospective
cohort
435 (3464) CKC, LLETZ CIN2e3 7.2 yearsb 1.2 yearsc 2 (a) Hospital records
(b) Hospital records
and The Netherlands
nationwide network
and registry of
histopathology and
cytopathology
e e
Kreimer,
2012
Costa Rica Retrospective
cohort
352 (2082) CKC, LLETZ CIN2e3 6 years No 3 (a) Guanacaste Natural
History Study (a
population-based study
in a rural province)
(b) Costa-Rican
population-based
cancer registry
e e
Rapiti,
2012
Switzerland Retrospective
cohort
2658 (35 946) Excision (hysterectomy,
CKC, LLETZ, LC);
ablation (LA,
electrocautery,
diathermy, CC);
hysterectomy was upon
patient’s request; 103
women had no
treatment
CIN3 (in 275
women,
diagnosis was
cytological)
11.1 years 0.5 years 17 (a) and (b) Geneva
Cancer Registry
General female
population from
the Geneva canton
SIR
Rebolj,
2012
The Netherlands Retrospective
cohort
38 956
episodese
(56 956
women-years)
NR (type of treatment
not consistently
registered; because
only patients treated
during the 1990s or
2000s were included,
we assumed that
hysterectomy was
carried out in relatively
few cases)
CIN1e3 1.5 women-years
per episodeb
w2 yearsf 20 (a) and (b)
Dutch nationwide
network and register of
histopathology and
cytopathology (PALGA)
Women from the
whole of The
Netherlands with
normal smears and
without previous
CIN
HR (adjusted
for year in f-u)
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218 https://doi.org/10.1016/j.annonc.2019.11.004Risk of bias assessment
The risk of bias assessment of the included studies is pre-
sented in supplementary Table S3, available at Annals of
Oncology online. Only two publications scored a high risk of
bias in one or more domains.38,47 The risk of selection bias
was deemed to be moderate in ﬁve studies4,38,39,43,46 that
did not have histological conﬁrmation of CIN for the whole
cohort. The risk of attrition bias was overall deemed to be
low, as all studies used centralised registries. The risk of bias
on prognostic factor measurement (i.e. treatment of CIN)
was moderate in fourteen cohorts,5,8,36e38,40e42,44,51,53e57
as these may have included women with untreated CIN
grade 2 (CIN2)37,40,42,53 or women treated with hysterec-
tomy.5,8,36e38,40e42,44,51,54e57 The lack of lag period be-
tween treatment and the start of follow-up introduced a
moderate risk for outcome measurement bias in six
studies.39,41,43,51,52,55 Lack of adjustment for age or calendar
period introduced a moderate risk of bias in two studies48,53
and was unclear in another two.43,45 Statistical analysis and
reporting did not lead to an increase in the risk of bias apart
from two studies, due to selected grouping of treatment
modalities47 or a case-control design.38Cervical cancer
The pooled absolute IR of cervical cancer after treatment of
CIN per 100 000 woman-years was reported in 11 cohorts
(IR 39, 95% CI 22e69; I2 99%; 11 cohorts, 1155 cancers,
5 562 889 woman-years) (Figure 2; supplementary Table S4
and supplementary Figure S1, available at Annals of
Oncology online).7,8,35,41e43,47e49,51e53 In the subgroup
analyses, the IR for older women (50 years) was 38 (1e
116) and for younger (<50 years) was 35 (0.020e53). The
rate increased as the grade of treated CIN increased (CIN1:
29, 17e48; CIN2: 36, 19e69; CIN3: 36, 17e76), and was the
highest during the ﬁrst decade (<10 years: 38, 33e44; 10e
20 years: 31, 24e40; >20 years: 32, 20e46). Five cohorts
reported on IR after excisional treatment (IR 60, 20e179, I2
99%; ﬁve cohorts, 265 cancers, 797 848 woman-
years).35,43,45e47 One cohort assessed IR after ablative
treatments46 and one after cryotherapy7,49; meta-analysis
was not possible.
The risk for cervical cancer after any local treatment of any
grade of CIN was found to be higher in treated women rather
than the reference population (RR 3.30, 2.57e4.24, I2 83%;
nine cohorts, 1145 cancers, 229 118 treated women)
(Figure 3; supplementary Table S5 and supplementary
Figure S2, available at Annals of Oncology
online).7,8,35,41,42,48,49,51e53 The RR for women over the age
of 50 was 7.15, 4.75e10.76, I2 0%; two cohorts, eight can-
cers, 313 treated women. For women under 50 at the time of
diagnosis, RR was 4.01, 1.47e10.95, I2 0%; two cohorts, 29
cancers, 2345 treated women. The RR for treated CIN3 le-
sions alone was 3.09, 2.18e4.39, I2 90%; six cohorts, 946
cancers, 178 919 treated women; meta-analytical pooling for
other grades was not possible. The RR for cervical cancer was
high after excisional treatment (RR 2.04, 1.88e2.21, I2 0%;
three cohorts, 260 cancers, 77 657 treated women). ThereVolume 31 - Issue 2 - 2020
Table 2. Characteristics of studies on incidence of cancers other than cervical, and on cervico-vaginal cancer mortality after treatment of cervical intraepithelial neoplasia (CIN)
Author, year Country Study design N treated Treatment method Degree of
treated CINa
Follow-up time
(median)b
Lag periodc Outcomes used
in meta-analysis
Ascertainment of
(a) exposure
(b) outcome
Reference population Effect
estimate
Pettersson, 1990 Sweden Retrospective
cohort
56 116 NR (conisation was
the usual
procedure;
hysterectomy was
carried out in
relatively few
cases)
CIN3 8.1 yearsb 1 year Other cancers:
corpus uterus,
ovaries, breast
(a) and (b) Swedish
National Cancer
Registry
General Swedish
female population
SIR
Bjorge, 1995 Norway Retrospective
cohort
37 001 NR (conisation was
the usual Tx;
alternatively,
hysterectomy)
CIN3 9.1 yearsb 1 year Other cancers:
overall, corpus
uterus, ovaries/
fallopian tubes,
colon/rectum,
breast, lung/
bronchus/
trachea, female
anogenital HPV-
related (vagina,
vulva, cervix)
(a) and (b) Cancer
Registry of Norway
General Norwegian
female population
SIR
Frisch, 1995 Denmark Retrospective
cohort
30 294 NR (some women
might have
received no
treatment;
hysterectomies
might have been
included)
CIN3 12.4 yearsb No Other cancers:
lung
(a) and (b) Danish
Cancer Registry
General Danish female
population
SIR
Levi, 1996 Switzerland Retrospective
cohort
2190 NR CIN3 10.1 yearsb NR Other cancers:
overall, corpus
uterus, breast
(a) and (b) Vaud
Cancer Registry
General female
population from Swiss
canton of Vaud
SIR
Evans, 2003 UK Retrospective
and prospective
cohort
59 519 NR (<10% had
radical surgery; NR
if all women had Tx
but most probably
did because only
CIN3 cases were
included)
CIN3 8 yearsb No Other cancers:
overall, vulva,
vagina, corpus
uterus, ovaries,
anus, colon/
rectum, breast,
lung, cervix/
vagina, female
anogenital HPV-
related (vagina,
vulva, cervix,
anus)
(a) TCR
(b) Prospective f-u
(until 1982) for
patients with CIN
diagnosed before
1971; retrospective
f-u through NHS
Cancer Registry for
patients with CIN
diagnosed after 1970
General female
population covered by
TCR
SIR
Taylor, 2006 USA Retrospective
cohort
56 020 NR CIN3 5 years No Other cancers:
ovaries, lung
(a) and (b) California
Cancer Registry
General female
population from
California
SIR
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Table 2. Continued
Author, year Country Study design N treated Treatment method Degree of
treated CINa
Follow-up time
(median)b
Lag periodc Outcomes used
in meta-analysis
Ascertainment of
(a) exposure
(b) outcome
Reference population Effect
estimate
Edgren, 2007 Sweden Retrospective
cohort
125 292 NR (CIN has
traditionally been
treated by CKC, LC,
cryosurgery, LLETZ;
5% were treated
with hysterectomy)
CIN3 18.4 yearsb 1 year Other cancers:
vulva, anus,
rectum, female
anogenital HPV-
related (vagina,
vulva, anus)
(a) and (b) Swedish
Cancer Registry
Women without
previous history of
CIN3
RR (adjusted
for age,
calendar period,
socioeconomic
status and
parity)
McCredie, 2010 Australia
and New
Zealand
Retrospective
cohort
72 CKC CIN3 27.5 years >w2.5
yearsc
Other cancers:
cervix/vagina
Mortality: cervix/
vagina
(a) Records of
National Women’s
Hospital
(b) Medical records,
histopathological
review or cancer and
death registries
General female
population from New
Zealand
SIR
Jakobsson, 2009
for mortality,
2011 for other
cancers
Finland Retrospective
cohort
26 876 for
other
cancers;
25 827 for
mortality
Excision (CKC,
LLETZ, LC); ablation
(LA,
electrocoagulation,
CT); other (other
excision, cervix
amputation etc.)
CIN1e3a 8.4 yearsb f-u started
at end of
calendar
year
of CIN
treatmentd
Other cancers:
overall, vulva,
vagina, corpus
uterus, ovaries,
anus, colon/
rectum, breast,
lung, cervix/
vagina, female
anogenital HPV-
related (vagina,
vulva, cervix,
anus)
Mortality: cervix
(a) National Hospital
Discharge Register
(b) Finnish Cancer
Registry for other
cancers; Finnish
Cause-of-Death
Register for mortality
General Finnish female
population
SIR
Strander, 2007
for other cancers,
2014 for other
cancers and
mortality
Sweden Retrospective
cohort
132 493
in 2007;
150 883
in 2014
NR (the Swedish
Cancer Register
does not include
date on treatment;
hysterectomies
have been
included)
CIN3 17.5 yearsb in
2007; 20.9b
in 2014
1 year Other cancers:
vagina (in 2007),
cervix/vagina (in
2014)
Mortality: cervix/
vagina
(a) Swedish Cancer
Registry
(b) Swedish Cancer
Registry for other
cancers; Swedish
Cause-of-Death
Register for mortality
General Swedish
female population
SIR
Saleem, 2011 USA Retrospective
cohort
124 075 NR (hysterectomies
might have been
included; NR if all
women had Tx but
most probably did
because only CIS
cases were
included)
CIN3 NR 1 year Other cancers:
anus
(a) and (b) SEER
registry (large
population-based
registry from 17
regions)
General female
population covered by
SEER registry
SIR
Gaudet, 2014 Canada Retrospective
cohort
54 320 NR (hysterectomies
might have been
included; NR if all
women had Tx but
most probably did
because only
CIN2þ cases were
included)
CIN2e3 10.1 years 0.5 years Other cancers:
vulva, vagina,
anus, female
anogenital HPV-
related (vulva,
vagina, anus)
(a) British Columbia
Cervical Cancer
Screening Program
(b) British Columbia
Cancer Registry
General female
population from British
Columbia
SIR
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Table 2. Continued
Author, year Country Study design N treated Treatment method Degree of
treated CINa
Follow-up time
(median)b
Lag periodc Outcomes used
in meta-analysis
Ascertainment of
(a) exposure
(b) outcome
Reference population Effect
estimate
Kirkegard, 2014 Denmark Retrospective
cohort
83 008 Cervical conisation
(‘minor surgical
procedure’, thus
hysterectomies
have probably been
excluded)
NR (probably
any CIN,
histological
or cytological)
14.9 years No (lag
period only
for SIR of
cancer
incidence
in the time
window
1e5 years,
but not for
SIR of
overall
cancer
incidence)
Other cancers:
colon/rectum
(a) Danish National
Patient Registry
(b) Danish Cancer
Registry
General Danish female
population
SIR
Coffey, 2016 UK Case-control
study (nested
case-control in
the Million
Women Study)
797 vulval
cancers in
a cohort of
1.3 million
women
aged 49e65
years;
19/797
had a
history
of CIN3
NR (hysterectomies
might have been
included; NR if all
women with CIN3
had Tx but most
probably did
because the
likelihood of
expectant
management of
CIN3 is low)
CIN3a 13.8 yearsb,e 3 years Other cancers:
vulva
(a) and (b) UK
National Health
Service Central
Registers (NHSCR)
(self-reported data
from the recruitment
questionnaire were
used to deﬁne most
exposures, but
NHSCR was used for
ascertainment of
CIN3)
Women with vulval
cancer but no previous
CIN3 diagnosis (case-
control study)
RR (adjusted
for smoking,
alcohol, BMI,
diabetes, age
at menarche,
oral contraceptive
use, parity,
prior tubal
ligation, prior
hysterectomy
and deprivation)
Sand, 2016 Denmark Retrospective
cohort
156 290 NR (hysterectomies
might have been
included; some
women might have
received no Tx)
CIN2e3 13.6 yearsb 1 year Other cancers:
vulva, vagina,
anus, female
anogenital HPV-
related (vulva,
vagina, anus)
(a) Danish Cancer
Registry & Pathology
Data Bank
(b) Danish Cancer
Registry
Denmark population
without history of
CIN2/3
HR (adjusted
for age and
education)
Ebisch, 2017 The
Netherlands
Retrospective
cohort
89 018 NR (hysterectomies
might have been
included; NR if all
women had Tx but
most probably did
because only CIN3
cases were
included)
CIN3 14 1 year Other cancers:
vulva, vagina,
anus, female
anogenital HPV-
related (vulva,
vagina, anus)
(a) and (b) Dutch
nationwide registry
of histopathology
and cytopathology
(PALGA; Houten, The
Netherlands)
Dutch population
without history of CIN3
RR (adjusted
for age)
BMI, body mass index; CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ; CKC, cold knife conisation; CT, cryotherapy; f-u, follow-up; HPV, human papillomavirus; HR, hazard ratio; LA, laser ablation; LC, laser conisation; LLETZ, large loop
excision of the transformation zone; N, number; NR, not reported; RR, relative risk; SIR, standardised incidence ratio; TCR, Thames Cancer Registry; Tx, treatment.
a Some women had cytological diagnosis (or not reported).
b Mean if median is not reported.
c No lag period, but we were able to exclude cancers occurring during the ﬁrst 6 or 12 months after treatment (or no cancers occurred during the ﬁrst 6 or 12 months).
d This means that the lag period varied from 0 to 12 months, depending on the month when treatment was carried out.
e This was a nested case-control from the Million Women Study and the mean reported is for a cohort of 1.3 million women aged 49e65 years.
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Figure 2. Pooled incidence rate of cervical cancer per 100 000 woman-years.
Subgroup analyses according to age at cervical intraepithelial neoplasia (CIN) treatment, treatment method for CIN, CIN grade, and length of follow-up.
CI, conﬁdence interval; IR, incidence rate; N/A, not available (i.e. meta-analysis not possible); PI, prediction interval.
Annals of Oncology I. Kalliala et al.wasmuch uncertainty in the random-effects meta-analysis of
RR after ablative treatment because of only two studies
being includedwith non-overlapping CIs. A ﬁxed-effect meta-
analysis estimated the RR 2.69 (0.94e7.65) for ablation
(supplementary Figure S2, available at Annals of Oncology
online). The summary estimates for cervical RRs were highest
in the early follow-up period, but remained consistently
elevated thereafter. Our estimate for RR after 20 years was
more uncertain, due to the small sample size (RR 2.40, 0.83e
6.93, I2 0%). However, the inverse variance method (random-
or ﬁxed-effect) reduced uncertainty (RR 2.40, 1.60e3.60)Overall
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Anogenital HPV-related cancers
Eleven cohorts were included in the meta-analysis of the
RRs of anogenital HPV-related cancers (Figure 4;
supplementary Table S6 and supplementary Figure S3,
available at Annals of Oncology online).5,36e
38,40,44,46,47,50,52,56 The RR of vaginal cancer was elevated
in women treated for CIN (RR 10.84, 5.58e21.10, I2 82%; six
cohorts, 329 cancers, 518 516 treated women) and likewise . (.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Figure 4. Pooled relative incidence of cervical and other cancers and mortality from cervical and vaginal cancer after treatment of cervical intraepithelial neoplasia
(CIN) as compared with the reference population.
CI, conﬁdence interval; N/A, not available (i.e. meta-analysis not possible); PI, prediction interval; RR, relative risk.
I. Kalliala et al. Annals of Oncologyfor vulvar cancer (RR 3.34, 2.39e4.67, I2 64%; seven co-
horts, 455 cancers, 511 315 treated women), and anal
cancer (RR 5.11, 2.73e9.55, I2 92%; seven cohorts, 534
cancers, 635 390 treated women). The RR of cervical or
vaginal cancers combined were elevated compared with the
general population (RR 5.71, 1.18e27.58, I2 82%; four co-
horts, 1503 cancers, 237 350 treated women). Likewise, for
the risk of any anogenital HPV-related cancer (RR 3.69,
2.29e5.94; I2 45%; seven cohorts, 1360 cancers, 548 316
treated women).
Non-HPV-related cancers
Nine cohorts reported on the RR of non-HPV-related can-
cers (Figure 4; supplementary Table S6 and supplementary
Figure S3, available at Annals of Oncology online).39,46,50e
52,54e57 The risk of any cancer after CIN treatment was
slightly elevated compared with the general population (RR
1.14, 0.98e1.32, I2 84%; four cohorts, 3124 cancers,
125 586 treated women). By a different statistical technique
(random-effects inverse variance model) we obtained nar-
rower CIs (any cancer: RR 1.14, 1.04e1.25) (supplementary
Figure S3, available at Annals of Oncology online). The only
malignancy for which we had strong evidence that it had
higher risk amongst the treated was lung cancer (RR 1.82,
1.32e2.52, I2 86%; ﬁve cohorts, 700 cancers, 209 710
treated women).
Mortality
Three cohorts were included in the meta-analysis of the
mortality from cervical and/or vaginal cancer after CIN
treatment (Figure 4; supplementary Table S6 and
supplementary Figure S3, available at Annals of Oncology
online).4,5,47 We found that mortality from cervical/vaginal
cancer was elevated compared with untreated women, but
our estimate was uncertain (RR 5.04, 0.69e36.94, I2 90%;Volume 31 - Issue 2 - 2020three cohorts, 376 deaths, 176 782 treated women). Using
the random-effects inverse variance model, we obtained
narrower CIs (RR 5.04, 2.04e12.49) (supplementary
Figure S3, available at Annals of Oncology online).
Meta-analysis of mortality from only cervical cancer, other
cancers, or any cause was not possible because of the
inadequate number of studies.Subgroup and sensitivity analyses
The between-study heterogeneity of the absolute IR of
cervical cancer was reduced when subgroup analyses were
carried out according to CIN grade and length of follow-up.
In the subgroup analysis after treatment of CIN3 alone,
sensitivity analyses according to geography reduced het-
erogeneity (supplementary Table S4, available at Annals of
Oncology online).
For the RR of cervical cancer, heterogeneity was reduced
in subgroup analyses according to age and method of
treatment (supplementary Table S5, available at Annals of
Oncology online).
Including only European studies reduced heterogeneity
for anal, ovarian, cervical/vaginal, and any female HPV-
related anogenital cancer. For vaginal and vulvar cancer,
heterogeneity was still high for European countries, but
choosing studies only from Northern or Western Europe
reduced I2. For lung cancer, sensitivity analyses could not
explain the high heterogeneity (supplementary Table S6,
available at Annals of Oncology online). The effect estimates
did not markedly change in the sensitivity analyses, apart
from cervical/vaginal and anal cancer, where including only
European studies at low risk of bias and studies only from
Northern Europe, respectively, reduced the point estimates.
In order to conﬁrm that selection of SIR or RR/HR did not
affect point estimates or heterogeneity, we meta-analysed
studies with HR/RR and SIR separately, and found nohttps://doi.org/10.1016/j.annonc.2019.11.004 223
Annals of Oncology I. Kalliala et al.marked differences in the point estimates or heterogeneity.
In two outcomes (anal and any HPV-related female ano-
genital cancer) sensitivity analysis of RR/HR reduced het-
erogeneity, but this could be explained by inclusion of only
European studies for these two sensitivity analyses.
DISCUSSION
Main ﬁndings in the context of current literature
Although the cancer-preventive effect of local CIN treat-
ment is as high as 95%e99%,7,48 women after treatment
are thought to be at higher risk of cervical disease than the
general population. Our analysis estimated the pooled ab-
solute IR for cervical cancer to be 39/100 000 woman-years,
which is consistent with the only previously published
pooled analysis (56/100 000 woman-years).14 Our pooled
rate was slightly lower and likely more accurate, as we have
included only studies with centralised follow-up, eliminating
overestimates that may result from small single-arm studies
pooled in the previous report.14
Our ﬁndings show that the pooled cervical cancer RR
amongst treated women was three times higher than the
general population. This risk remains elevated for at least 20
years after the index treatment. These results were also in
agreement with a previously published report.14
The RR of other HPV-related anogenital cancers was also
markedly raised in treated as opposed to untreated women.
The risk of non-HPV-related malignancies was not increased
when compared with the general population, with the
exception of a twofold rise in lung cancer, possibly reﬂecting
a signiﬁcantly higher prevalence of smokers amongst
women treated for CIN, given that smoking is a known risk
factor for CIN.64 We found that mortality was ﬁve times
higher than that in the general population, although there
was uncertainty around this estimate.
In recent decades, there has been a transition from more
radical excision with cold knife conisation (CKC) that was
routinely practiced in the 1980s to laser conisation, and to
the less aggressive large loop excision of the transformation
zone (LLETZ) in the 1990s that is practiced predominantly to
date.8,65 The subsequent increased awareness that treat-
ment, particularly excisional, increases the risk of preterm
birth and other adverse reproductive outcomes in subse-
quent pregnancies66e71 has led to further reduction in the
radicality of treatment, with more clinicians opting for
smaller excision,72 or even ablative treatment.66 The pre-
viously published Cochrane review exploring the compara-
tive efﬁcacy of excision versus ablation was grossly
underpowered to show a difference for highly efﬁcacious
treatment; this would require a large, appropriately-
powered non-inferiority trial that has yet to be conduct-
ed.73 A recent meta-analysis provided indirect evidence that
LLETZ when compared with CKC, and incomplete as
compared with complete margin clearance, affects treat-
ment failure rates (7 versus 2% and 17 versus 4%, respec-
tively).3 The impact of less radical treatments on the future
risk of invasion remains unclear.5,74 Although we carried out
analyses for excisional and ablative techniques separately,224 https://doi.org/10.1016/j.annonc.2019.11.004these were not informative and were limited by the small
number of studies. In one study, the point estimate for
cervical cancer was higher after ablative than excisional
treatment.46 In two cohorts exploring the differences be-
tween treatment methods, cryotherapy was shown to in-
crease cervical cancer risk threefold when compared with
other local methods48 or CKC.49 The pooled RRs after
excisional or ablative treatment were elevated compared
with the reference population, although based on just a few
studies and small numbers of incident cancers.
There are a number of plausible theories explaining the
increase in the risk of cervical cancer after CIN treatment. A
number of cases predominantly diagnosed close to the in-
dex treatment may be a result of inadequate disease exci-
sion, disease hidden in the endocervical crypts, and
misdiagnosis of invasive malignancies as preinvasive. To
minimise the risk of inﬂating the pooled cancer incidence
due to misdiagnosis, all but one study used a lag-period of
at least 6 months from the time of treatment to capture
faults in diagnosis. Despite this, the incidence of cervical
cancer was comparatively higher in the early follow-up
periods, although this continued to be higher than the
general population for more than two decades. Residual
preinvasive disease within or outside of the endocervical
crypts is harder to detect and prevent after previous
treatment, as cytology and colposcopy can be more difﬁcult
to perform adequately and interpret.41 Avoiding heavy
cauterisation of the crater during treatment might decrease
the risk of ‘burying’ residual disease inside the crypts, which
subsequent cytology and colposcopy might not be able to
detect.
‘Lingering’ disease, persistent high-risk HPV infection, and
misdiagnosis could only partly explain the prolonged in-
crease in the risk of invasive cancer after CIN treatment in
some cases. The higher risk of all other HPV-related malig-
nancies and the slightly higher risk in women over the age
of 50 years suggest further possible explanations. Although
cervical cancer is not considered to be a hereditary disease,
there is evidence to suggest that genetic polymorphisms,75
variations in immune defences and an innate immune sys-
tem,76 microbiome predisposition77 and an inherent sensi-
tivity to HPV infection and persistence in some individuals
may increase their risk of HPV-related malignancies. These
women are often particularly sensitive to the infection and
rapidly get re-infected even if they clear this at the time of
treatment.
This analysis may inform more personalised screening
strategies in women previously treated for CIN and assist
decision-making for clinicians and health policy makers. The
interruption of cervical screening for previously treated
women at an age similar to that of the general population
has been long debated.78 Advocates of prolonged screening
for the subset of treated women note that the second peak
in cervical cancer incidence, as well as peak incidence of
other HPV-related cancers, is observed after the end of
screening,79 whereas cervical cancer mortality increases
with advancing age.80 Our ﬁndings support this notion, as
the risk remained high for more than 20 years afterVolume 31 - Issue 2 - 2020
I. Kalliala et al. Annals of Oncologytreatment and was slightly higher for women over 50 years
old. Prolonged screening after treatment for 20 years, or
even for the remainder of their lifetime, may enhance pre-
vention of cervical cancer, but may also promote early
detection of asymptomatic vulvar, vaginal, and other HPV-
related neoplasms post-treatment, as these women will
attend health services and have an examination of the
anogenital area. Further recommendations on strategies for
the prevention and early detection of non-cervical malig-
nancies are limited by the absence of currently validated
screening tools. Future research should further explore the
value and cost-effectiveness of preventative interventions
for other HPV-related malignancies (such as vault sample
and/or colposcopic inspection in hysterectomised women
for the prevention of vaginal and vulvar cancer, and anal
sampling with anoscopy for anal cancer). With the intro-
duction of the hrHPV DNA test in primary screening and HPV
prophylactic vaccination, current screening programmes
have undergone substantial reconﬁguration making previ-
ously published evidence difﬁcult to apply to awaited future
screening structures. The expected prolongation of screening
intervals may allow extension of current screening pro-
grammes beyond the age of 65 years, in line with prolonged
life expectancy, particularly for treated women.These results
also support further education for lifestyle, sexual, and
behaviour changes that may enhance the prevention of
HPV-related malignancies, and further emphasise the need
for smoking cessation initiatives.Strengths and weaknesses
This is the ﬁrst systematic review and meta-analysis of
observational studies with centralised follow-up assessing
cancer incidence and mortality after treatment of CIN.
Centralised registry data offer great advantages in mini-
mising losses to follow-up due to population movement,
and attrition bias that can arise from women facing barriers
to healthcare access or without symptoms prompting them
to seek medical advice, when based on the records of a
single clinic. The risk of bias in included studies was, overall,
considered to be low. Furthermore, we used the Knapp-
Hartung-Sidik-Jonkman method for our analyses, which is
known to outperform the traditional Wald type method,
particularly in the context of a limited number of studies.
This method usually produces more conservative estimates,
reduces the risk of spurious results, and is robust to the use
of different estimators for the between-study variance.
There were several limitations in our meta-analyses. In
some of these analyses, there was high between-study
heterogeneity, resulting in uncertainty in the estimated ef-
fects. Subgroup and sensitivity analyses according to age,
CIN grade, treatment method, or length of follow-up were
able to reduce heterogeneity to some extent, although
many included only a small number of studies. Further-
more, we could not reliably assess for small-study effects or
publication bias due to the dearth of studies. Finally, we
were unable to perform subgroup analyses for the status of
post-treatment test-of-cure (HPV testing and/or cytology atVolume 31 - Issue 2 - 20206 months) due to limitations in the published data. Future
studies should stratify cancer rates to HPV status after
treatment.Conclusions
Women treated for CIN have an increased incidence of not
only cervical, but of all HPV-related female genital tract
cancers, compared with the general population. Treated
women remain at increased risk for developing invasive
cervical cancer for more than 20 years. Our ﬁndings suggest
that a sufﬁciently long follow-up, perhaps lifelong, after the
end of organised screening may be warranted for this high-
risk population previously treated for CIN.
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